Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Followed by Mini-Allogeneic Stem Cell Transplant for Multiple Myeloma
NCT00014508Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Nov 2001
- Primary completion
- Feb 2007
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous peripheral blood stem cell transplantation in multiple myeloma (MM), sponsored by Eastern Cooperative Oncology Group. Primary endpoints: Incidence of early mortality, Incidence of early allogeneic graft failure at 100 days and 4 more. Started Nov 2001; status: completed.
02
Drugs
autologous peripheral blood stem cell transplantation
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00014508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00014508.